Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D

Annals of Oncology

Volumn 7, Issue 4, 1996, Pages 391-395

  Dannecker, C ^a   Possinger, K ^b   Classen, S ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Antiprogestins; Breast cancer cells; Estrogen receptors; Onapristone; Progesterone receptors; TGF beta

Indexed keywords

ANTIGESTAGEN; ESTROGEN RECEPTOR; MIFEPRISTONE; ONAPRISTONE; PROGESTERONE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; DRUG RECEPTOR BINDING; ESTROGEN ACTIVITY; GROWTH REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION;

EID: 0030037627     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010606     Document Type: Article

References (38)

1. Bardon S, Vignon F, Montcourrier P et al. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 1987; 47: 1441-8.
2. Classen S, Possinger K, Pelka-Fleischer R et al. Effect of onapristone and medroxyprogesterone acetat on the proliferation and hormone receptor concentration of human breast cancer cells. J Steroid Biochem Mol Biol 1993; 45: 315-9.
3. Schneider MR, Michna H, Nishino Y et al. Antitumor activity of the progesterone antagonist ZK 99.299 and RU 486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and MNU-induced mammary tumor model of the rat. Eur J Cancer Clin Oncol 1989; 25: 691-701.
4. Schneider MR, Michna H, Habenicht UF et al. The tumor-inhibiting potential of the progesterone antagonist onapristone in the human mammary carcinoma T61 in nude mice. Cancer Res Clin Oncol 1992; 118: 187-9.
5. Romieu G, Maudelonde T, Ulmann A et al. The antiprogestin Ru 486 in advanced breast cancer: Preliminary clinical trial. Bull Cancer 1987; 74: 455-61.
6. Klijn JGM, De Jong FH, Bakker et al. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 1989; 49: 2851-6.
7. Herrman W, Wyss R, Riondel A et al. Effet d'un steroid anti-progesterone chez la femme - interuption du cycle menstruel et de la grossesse au debut. C R Acad Sci Paris 1982; 294: 933-8.
8. Neef G, Beier S, Elger W et al. New steroids with antiprogestational and anticlucocorticoid activities. Steroids 1984; 44: 349-72.
9. Michna H, Nishino Y, Neef G et al. Progesterone antagonists: Tumor-inhibiting potential and mechanism of action. J Steroid Biochem Mol Biol 1992; 41: 339-48.
10. Cullen KJ, Yee D, Bates SE et al. Regulation of human breast cancer by secreted growth factors. Acta Oncol 1989; 28: 835-9.
11. Colletta AA, Wakefield LM, Howell FV et al. The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. J Clin Invest 1991; 87: 277-83.
12. Knabbe C, Lippman ME, Wakefield LM et al. Evidence that transforming growth factor is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417-28.
13. Wakefield LM, Colletta AA, McCune BK et al. Role for transforming growth factor β in the genesis, prevention, and treat-ment of breast cancer. In Dickson RB, Lippman ME (eds): Genes, Oncogenes and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer. Boston: Kluwer Academic Publishers 1992; 97-136.
14. Roberts AB, McCune BK, Sporn MB. TGF-beta: Regulation of cellular matrix. Kidney Int 1992; 41: 557-9.
15. Sporn MB, Roberts AB. Transforming Growth Factor-β: Recent progress and new challenges J Cell Biol 1992; 119: 1017-21.
16. Wakefield LM, Smith DM, Flanders KC et al. Latent transforming growth factor-beta from human platelets. A high molecular complex containing precursor sequences. J Biol Chem 1988; 263: 7646-54.
17. Roberts AB, Anzono MA, Wakefield LM et al. Type β transforming growth factor: A bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 1985; 82: 119-23.
18. Miyazono K, Heldin CH. Latent forms of TGF-beta: Molecular structure and mechanisms of activation. Ciba Foundation Symposium 1991; 157: 81-92.
19. Pircher R, Jullien P, Lawrence DA. β-Transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Comm 1986; 136: 30-7.
20. Lyons RM, Keski-Oja, Moses HL. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J Cell Biol 1988; 110: 1361-7.
21. Darbre P, Yates J, Curtis S et al. Effect of estradiol on human breast cancer cells in culture. Cancer Res 1983; 43: 349-54.
22. Lowry OH, Rosenbrough NJ, Farr AL et al. Protein measurement with folin phenol reagent. J Biol Chem 1951; 193: 265-75.
23. Wakefield M, Smith DM, Masui T et al. Distribution and modulation of the cellular receptor for transforming growth factor-β. J Cell Biol 1987; 105: 965-75.
24. Frolik CA, Wakefield LM, Smith DM et al. Characterization of a membrane receptor for transforming growth factor β in nor mal rat kidney fibroblasts. J Biol Chem 1984; 259: 10995-1000.
25. Michna H, Schneider MR, Nishino Y et al. The antitumor mechnaism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem 1989; 34: 447-53.
26. Michna H, Nishino Y, Neef G et al. Progesteron antagonists: Tumor-inhibiting potential and mechanism of action. J Steroid Biochem Mol Biol 1992; 41: 339-48.
27. Masui T, Wakefield LM, Lechner JF et al. Type β transforming growth factor is the primary differntiation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Acad Sci USA 1986; 83: 2438-42.
28. Yanagihara K, Tsumuraya M. Transforming growth factor β1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res 1992; 52: 4042-5.
29. Heimark RL, Twardzik DR, Schwarz SM. Inhibition of endothelial cell regeneration by type-beta transforming growth factor from platelets. Science 1986; 233: 1078-80.
30. Laiho M, DeCaprio JA, Ludlow JW et al. Growth inhibtion by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 1990; 62: 175-85.
31. van den Berg HW, Lynch M, Martin JHJ. The relationship between affinity of progestins and antiprogestins for the receptor in breast cancer cells (ZR-PR-LT) and ability to down-regulate the receptor: Evidence for heterospecific modulation via the glucocorticoid receptor. Eur J Cancer 1993; 29: 1771-5.
32. Jeng MH, Langan-Fahey SM, Jordan VC. Estrogenic actions of RU486 in hormone-responsive MCF7 human breast cancer cells-Endocrinology 1993; 132: 2622-30.
33. Bakker GH, Setyono-Han B, Portengen H et al. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology 1989; 125: 1593-8.
34. Butta A, MacLennan K, Flanders KC et al. Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261-4.
35. Horwitz KB, McGuire WL. Nuclear mechanisms of estrogen action. J Biol Chem 1978; 253: 8185-91.
36. Namer M, Lalanne C, Balieu EE. Increase of progesterone receptor by tamoxifen as an hormonal challenge test in breast cancer. Cancer Res 1989; 40: 1750-2.
37. Noguchi S, Motomura K, Inaji H et al. Up-regulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 1993; 71: 1266-72.
38. Eppendberger U, Hasmann M, Küng W. Pharmacological properties of Droloxifene (Abstr 10.11.02). Proc 15th Internat Cancer Congress, Hamburg. J Cancer Res Clin Oncol 1990; 116 (Suppl).